What question did this study set out to answer?

The study investigates the relationship between plasma P-tau217 levels and cognitive decline associated with Alzheimer's disease co-pathology in Lewy body disorders.

March 21, 2026Open Access

Association between Plasma P‐tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's Disease

Key Points

The study investigates the relationship between plasma P-tau217 levels and cognitive decline associated with Alzheimer's disease co-pathology in Lewy body disorders.
Analyzed plasma P-tau217 levels in individuals with Parkinson's disease
Evaluated associations with cognitive decline
Considered imaging and clinical outcomes
Higher plasma P-tau217 levels correlate with increased cognitive decline
Indicates potential for P-tau217 as a biomarker for Alzheimer's disease co-pathology

Abstract

Plasma P-tau217 detects Alzheimer's disease co-pathology in Lewy body disorders and predicts cognitive decline. Future studies will evaluate associations between plasma P-tau217 and imaging and clinical outcomes, in consideration for use of amyloid-targeting therapies in Lewy body disorders. ANN NEUROL 2026.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Thomas F. Tropea

Patricia Aldea Stevenson

Matthew Flitter

Journals

Annals of Neurology

Actions

Institutions

University of Pennsylvania

Eli Lilly (United States)

Philadelphia University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Association between Plasma P‐tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's Disease

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider